CTLA4 and esophageal cancer: Fuse the deglycosylated antibody with a CTLA-4 inhibitor to form a bifunctional macromolecule, achieving the dual effects of increased T-cell infiltration and tumor metabolism inhibition in an esophageal cancer model, with a complete remission rate of 40%.